CN119031907A - 用于治疗视网膜色素变性的药物组合物 - Google Patents

用于治疗视网膜色素变性的药物组合物 Download PDF

Info

Publication number
CN119031907A
CN119031907A CN202380030920.5A CN202380030920A CN119031907A CN 119031907 A CN119031907 A CN 119031907A CN 202380030920 A CN202380030920 A CN 202380030920A CN 119031907 A CN119031907 A CN 119031907A
Authority
CN
China
Prior art keywords
pvs
statin
pharmaceutical composition
mice
pbs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380030920.5A
Other languages
English (en)
Chinese (zh)
Inventor
村上祐介
园田康平
池田康博
古贺恒行
T·松尾
江口畅次朗
古家博信
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Pharmaceutical Co ltd
Kyushu University NUC
Original Assignee
Advanced Pharmaceutical Co ltd
Kyushu University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Pharmaceutical Co ltd, Kyushu University NUC filed Critical Advanced Pharmaceutical Co ltd
Publication of CN119031907A publication Critical patent/CN119031907A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380030920.5A 2022-01-28 2023-01-26 用于治疗视网膜色素变性的药物组合物 Pending CN119031907A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022012146 2022-01-28
JP2022-012146 2022-01-28
PCT/JP2023/002470 WO2023145831A1 (ja) 2022-01-28 2023-01-26 網膜色素変性症を治療するための医薬組成物

Publications (1)

Publication Number Publication Date
CN119031907A true CN119031907A (zh) 2024-11-26

Family

ID=87471563

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380030920.5A Pending CN119031907A (zh) 2022-01-28 2023-01-26 用于治疗视网膜色素变性的药物组合物

Country Status (5)

Country Link
US (1) US20250144041A1 (https=)
EP (1) EP4470531A4 (https=)
JP (1) JPWO2023145831A1 (https=)
CN (1) CN119031907A (https=)
WO (1) WO2023145831A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004149480A (ja) * 2002-10-31 2004-05-27 Saisentan Igaku Kenkyusho:Kk 経口又は経皮投与用の眼科疾患治療剤
WO2004103960A2 (en) * 2003-05-16 2004-12-02 Ambit Biosciences Corporation Compounds and uses thereof
US10568860B2 (en) * 2006-08-30 2020-02-25 Kowa Co., Ltd. Pharmaceutical composition containing statin-encapsulated nanoparticle
WO2008044339A1 (en) * 2006-10-13 2008-04-17 Aqumen Biopharmaceuticals K.K. Therapeutic/preventive agent for intraocular disease containing statin compound
CN101959542B (zh) * 2007-12-25 2014-11-12 国立大学法人山口大学 药物传递系统
JP2023517582A (ja) * 2020-03-11 2023-04-26 ウニヴェルジテート レーゲンスブルク 眼疾患の処置における使用のためのナノ粒子
JP6978016B1 (ja) 2020-07-01 2021-12-08 株式会社システムフォワード 来場者管理システム及び来場者管理方法

Also Published As

Publication number Publication date
WO2023145831A1 (ja) 2023-08-03
EP4470531A1 (en) 2024-12-04
US20250144041A1 (en) 2025-05-08
EP4470531A4 (en) 2026-01-14
JPWO2023145831A1 (https=) 2023-08-03

Similar Documents

Publication Publication Date Title
Parker et al. Three‐Year Safety Results of SAR422459 (EIAV‐ABCA4) Gene Therapy in Patients With ABCA4‐Associated Stargardt Disease: An Open‐Label Dose‐Escalation Phase I/IIa Clinical Trial, Cohorts 1‐5
Yurkewicz et al. The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury
TWI658828B (zh) 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
TWI695717B (zh) １,２,４-二唑苯甲酸之鹽及醫藥組合物
US10272070B2 (en) Method for treating neurodegenerative diseases
JP6625064B2 (ja) 眼障害を治療かつ診断するための組成物および方法
US20220323550A1 (en) Pegloticase for treatment of gout in renal transplant recipients
KR101779991B1 (ko) 병소성 전정 질환을 치료하기 위한 세로토닌 5-ｈｔ3 수용체 길항제의 용도
Henrich et al. Anatomical and functional outcome in brilliant blue G assisted chromovitrectomy
JP2019506439A (ja) ターゲティングされた治療用リソソーム酵素融合タンパク質、関連する製剤、およびその使用
Sethna et al. Proposed therapy, developed in a Pcdh15-deficient mouse, for progressive loss of vision in human Usher syndrome
US20150152084A1 (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
KR20260027123A (ko) 폴리시알산-중합체 컨쥬게이트 및 나노입자
Ahsanuddin et al. 3-D OCT imaging of hyalocytes in partial posterior vitreous detachment and vaso-occlusive retinal disease
JPH09505826A (ja) ぜん息治療薬の製造にテオフィリンを使用する使用法
EP4342471A1 (en) Method for modulating neuropathies
CN119031907A (zh) 用于治疗视网膜色素变性的药物组合物
JP7737395B2 (ja) サイトカインストーム症候群の治療のためのペプチド
Üçer et al. How does Covid-19 affect the choroidal structures at the early post-infectious period?
Zhang et al. Case report: Ultrasound biomicroscopy as a guide for the selection of injection sites for dexamethasone intravitreal implant (Ozurdex) for peripheral granulomatous ocular toxocariasis in children
Blohm et al. Clinical utility, dose determination, and safety of ocular contrast‐enhanced ultrasonography in horses: A pilot study
Ramesh et al. The Holistic Spectrum of Thrombotic Ocular Complications: Recent Advances with Diagnosis, Prevention, and Management
US20250222119A1 (en) Engineering of multifunctional peptides for controlled drug delivery
Liang et al. Effect of troxerutin and cerebroprotein hydrolysate injection for the treatment of acute cerebral infarction: A multi-center randomized, single-blind and placebo-controlled study
JP6153838B2 (ja) 血管透過性抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination